Clinical Trial Update: Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the aflibercept FYB203 biosimilar versus Eylea in neovascular age-related macular degeneration, reporting efficacy and safety results w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• EYLEA (Aflibercept)
• FYB203 (aflibercept)

Snippet

Sponsor: Bioeq GmbH | Conditions: Neovascular Age-related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2025-11-13